Health · 16 views
Ixekizumab + Tirzepatide boosts psoriatic arthritis outcomes more than Ixekizumab monotherapy
Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults wit…
AI Summary
Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNowMore from Health
Continue reading recent Health coverage
- Sleep replay of learned skills can occur independently of the hippocampus, mouse study findsContinue reading
- The US public is fed up with RFK Jr. To really ‘make America healthy again’, it should look to Europe | Devi SridharContinue reading
- Six things to know about infrared workouts—by a fitness expertContinue reading